Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Hepatocellular Carcinoma Clinical Trials

39 recruiting trials for Hepatocellular Carcinoma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
39
Total Trials
39
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGPhase 1NCT03198546

GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression

The third/fourth generation of CAR-T cells that target GPC3 (GPC3-CART cell) and/or soluble TGFβ (GPC3/TGFβ-CART )have been constructed and their anti-HCC function has been...

Sponsor: Second Affiliated Hospital of Guangzhou Medical UniversityEnrolling: 302 locations
RECRUITINGPhase 2NCT06902246

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

The purpose of this study is to determine the effects that Regorafenib in combination with Yttrium-90 (Y-90) radioembolization has on patients with unresectable hepatocellular...

Sponsor: University of MiamiEnrolling: 301 location
RECRUITINGPhase 2 / Phase 3NCT06904170

Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma

Liver cancer is a highly lethal malignancy and has become increasingly important in western countries. The management of liver cancer is complex. In advanced disease, two...

Sponsor: UNICANCEREnrolling: 19611 locations
RECRUITINGNCT06475118

Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepatocellular...

It is known that some substances present in the blood, called 'myokines,' influence muscle loss. Some may accelerate this loss, while others may prevent it. Inflammatory...

Sponsor: CHU de ReimsEnrolling: 1391 location
RECRUITINGPhase 2NCT05775159

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced...

GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with...

Sponsor: AstraZenecaEnrolling: 29420 locations
RECRUITINGNCT06537908

Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC

This study is being done to analyze the safety, tolerability, and efficacy of treatment using combination of anti-VEGF and anti-PD-1/PDL1 antibodies for patients with advanced...

Sponsor: Shanghai Zhongshan HospitalEnrolling: 501 location
RECRUITINGPhase 1 / Phase 2NCT06590246

A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)

This single-arm, open-label multicenter Phase I/II study will evaluate the safety, tolerability, anti-tumor activity, pharmacokinetics (PK), pharmacodynamics (PD), and...

Sponsor: Shanghai AbelZeta Ltd.Enrolling: 1212 locations
RECRUITINGNCT05143619

Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis...

This study evaluates a concept called 'Teaching the Teachers' and whether it is helpful in disseminating guidelines on the national and international levels. "Teaching the...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 1001 location
RECRUITINGNCT05359939

A Head-to-head Comparison of MRI, CT, 18F-FDGal and 18F-choline in Patients With Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the most common primary liver tumour and is the fourth leading cause of cancer-related death worldwide. In Denmark, the incidence of HCC is 5.2...

Sponsor: University of AarhusEnrolling: 501 location
RECRUITINGNCT06519578

Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma

This study is a prospective cohort study aimed at comparing the efficacy and safety of RALOX-HAIC and FOLFOX-HAIC in the treatment of hepatocellular carcinoma. It is planned to...

Sponsor: RenJi HospitalEnrolling: 11152 locations
RECRUITINGNCT04365751

To Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular Carcinoma

The study was a prospective multicenter cohort control study, which was divided into 1:1 groups to compare the clinical efficacy of percutaneous microwave ablation and...

Sponsor: Chinese PLA General HospitalEnrolling: 11341 location
RECRUITINGPhase 1 / Phase 2NCT06294548

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

This is a phase Ib/II, dose escalation and dose expansion study of valemetostat (DS-3201) with atezolizumab and bevacizumab in patients advanced Hepatocellular carcinoma (HCC) who...

Sponsor: University of Alabama at BirminghamEnrolling: 451 location
RECRUITINGPhase 2NCT06218420

Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enlisted for...

The aim of this trial is to carry out the first prospective multicentric study which evaluates the efficacy and the safety of SBRT in HCC patients enlisted for LT and not suitable...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 1391 location
RECRUITINGNCT06541990

Psychoeducational Intervention for Patients With Hepatocellular Carcinoma

This study aims to refine and pilot test HARMONY, a psychoeducational intervention for patients with newly diagnosed hepatocellular carcinoma (HCC).

Sponsor: Massachusetts General HospitalEnrolling: 501 location
RECRUITINGNCT06345508

Early Detection of Liver Cancer by QUS

Worldwide, liver cancers are the third most common cause of cancer mortality. Even when liver cancer is suspected by blood tests, imaging is required to determine the location,...

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)Enrolling: 3281 location
RECRUITINGNCT06265350

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

This study intends to evaluate the efficacy and safety of cryoablation combined with Cardonilizumab and Bevacizumab in hepatocellular carcinoma with pulmonary metastases.

Sponsor: Sun Yat-sen UniversityEnrolling: 802 locations
RECRUITINGNCT04745390

Standard Versus Radiobiologically-Guided Dose Selected SBRT in Liver Cancer

Radiation is a standard treatment option for patients with liver cancer. Unfortunately, the tumour grows after radiation in many patients and radiation can harm normal tissues. A...

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sEnrolling: 1101 location
RECRUITINGPhase 1 / Phase 2NCT04864054

T-Cell Therapy (ECT204) in Adults With Advanced HCC

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell...

Sponsor: Eureka Therapeutics Inc.Enrolling: 207 locations
RECRUITINGNCT06077591

Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided...

Precision oncology aims to improve clinical outcome of patients by offering personalized treatment through identifying druggable genomic aberrations within their tumors. This is...

Sponsor: Chinese University of Hong KongEnrolling: 401 location
RECRUITINGPhase 1 / Phase 2NCT06795022

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in...

Sponsor: AstraZenecaEnrolling: 30420 locations
RECRUITINGNCT06537193

Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment

Hepatocellular carcinoma (HCC) often has a poor prognosis after curative treatment due to frequent recurrence. Post-surgery, 60-70% of HCC patients experience recurrence, rising...

Sponsor: Asan Medical CenterEnrolling: 4551 location
RECRUITINGNCT05994859

SIRT for Potentially Resectable HCC

This study is conducted to evaluate the efficacy and safety of Y-90 selective internal radiation therapy (SIRT) in patients with potentially resectable hepatocellular carcinoma...

Sponsor: Second Affiliated Hospital of Guangzhou Medical UniversityEnrolling: 351 location
RECRUITINGPhase 2NCT06558227

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular...

This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared...

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,LtdEnrolling: 901 location
RECRUITINGPhase 2NCT04204850

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

This is a phase 2 study that will assess the investigational drug, cabozantinib, in patients with liver cancer (specifically hepatocellular carcinoma) and who had received a liver...

Sponsor: University Health Network, TorontoEnrolling: 201 location
RECRUITINGNCT06519721

Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC

This study is a single-arm, open-label trial to clarify the safety and efficacy of the combined treatment of lenvatinib and VIC-1911 in patients with advanced liver cancer.

Sponsor: RenJi HospitalEnrolling: 151 location
RECRUITINGPhase 2NCT03259867

Combination of TATE and PD-1 Inhibitor in Liver Cancer

This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed...

Sponsor: Teclison Ltd.Enrolling: 543 locations
RECRUITINGPhase 1 / Phase 2NCT06527495

Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma

The current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in HCC through pharmacogenomic analysis of VEGFA and KDR genetic...

Sponsor: Assiut UniversityEnrolling: 1501 location
RECRUITINGNCT05810402

Liver Cancer and Immunotherapy in the Liquid Biopsy Era

The goal of this prospective clinical trial is to identify a predictive biomarker in patients with advanced HCC (stage B and C) using a combinatorial approach of the liquid...

Sponsor: University Hospital, MontpellierEnrolling: 601 location
RECRUITINGPhase 2NCT06553885

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

This study is a multi-indication, open-label, single-treatment arm, parallel-cohort phase II study of enfortumab vedotin in adult participants with advanced or metastatic...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 401 location
RECRUITINGPhase 1 / Phase 2NCT03093688

Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor

Invariant Natural killer T (iNKT) cells are a unique subset of lymphocytes that express homogeneous TCR recognizing KRN7000 which was up-regulated by many kinds of cancer cells....

Sponsor: Shanghai Public Health Clinical CenterEnrolling: 401 location
RECRUITINGPhase 2NCT06503146

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. \[18F\]FAPI-74 is a new PET...

Sponsor: National Cancer Institute (NCI)Enrolling: 3201 location
RECRUITINGPhase 1 / Phase 2NCT06362369

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens....

Sponsor: 7 Hills Pharma, LLCEnrolling: 1264 locations
RECRUITINGNCT04792463

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline...

Sponsor: Mohamed Abdel-RahmanEnrolling: 5001 location
RECRUITINGNCT05623150

CHronic Hepatopathies Associated with ALcohol Consumption and MetAbolic Syndrome

The aim is to determine the metabolic factors, host immune factors, and medical imaging data associated with the development of HepatoCellular Carcinoma (HCC) in patients with...

Sponsor: Institut National de la Santé Et de la Recherche Médicale, FranceEnrolling: 7101 location
RECRUITINGPhase 1NCT06617000

A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related

This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.

Sponsor: SCG Cell Therapy Pte. Ltd.Enrolling: 387 locations
RECRUITINGNCT06658782

Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of...

Aim: To use magnetic resonance imaging (MRI) scans without contrast to help improve diagnosis of liver cancer in people who are at increased risk of developing liver cancer....

Sponsor: University of OxfordEnrolling: 3002 locations
RECRUITINGNCT04525833

Liver Disease and Other Systemic Diseases

Examine the association of chronic liver diseases (including hepatitis B, hepatitis C, alcoholic liver disease, fatty liver, liver cirrhosis, and hepatocellular carcinoma) with...

Sponsor: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationEnrolling: 150001 location
RECRUITINGPhase 2NCT07285044

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve...

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer...

Sponsor: Mayo ClinicEnrolling: 271 location
RECRUITINGPhase 1NCT06910657

IDOV-Immune for Advanced Solid Tumors

This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not...

Sponsor: ViroMissile, Inc.Enrolling: 786 locations